MIP-1095 (TFA)

Product Description: MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled (131I labeled) as an imaging probe to indicate tumor progression. And 131I-MIP-1095 showed higher renal uptake in mice[1][2].

Applications: Cancer-programmed cell death

Formula: C21H26F3IN4O10

References: [1]Zechmann CM, et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92./[2]Kelly JM, et al. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. J Nucl Med. 2017 Sep;58(9):1442-1449.

Molecular Weight: 678.35

Compound Purity: 99.76

Research Area: Cancer

Solubility: DMSO : 125 mg/mL (ultrasonic)

Target: PSMA

• SKU: MEXHY-123733A-10
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-123733A-10
• Package Unit: 10 mg
• Quantity Unit: STK